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Cardiac troponin (cTn) I and T are structural proteins unique to the heart. Detection of cTn in peripheral blood indicates cardiomyocyte
damage. As acute myocardial infarction (AMI) is the most important cause of cardiomyocyte damage, cTns have become an integral part in
the diagnosis of AMI. For this indication, cTns are superior to all other biomarkers and therefore are the preferred marker for the diagnosis
of AMI. However, cTn indicates and provides an estimate of cardiomyocyte damage irrespective of its cause. The major limitation of con-
temporary cTn assays is that they are often not elevated during the initial hours of AMI. Recent advances in assay technology have led to
more sensitive and precise cTn assays that will have a profound impact on clinical practice. High-sensitive cTn (hs-cTn) assays have two dif-
ferentiating features from contemporary cTn assays: (i) detection of cTn in a majority of healthy persons and (ii) precise definition of what is
‘normal’ (¼the 99th percentile). Recent multicentre studies have shown that hs-cTn assays improve the early diagnosis of patients with sus-
pected AMI, particularly the early rule-out. To achieve best clinical use, cTn has to be interpreted as a quantitative variable. Rising and/or
falling levels differentiate acute from chronic cardiomyocyte damage. The terms ‘troponin-positive’ and ‘troponin negative’ should therefore
be avoided. ‘Detectable’ levels will become the norm and will have to be differentiated from ‘elevated’ levels. The differential diagnosis of a
small amount of cardiomyocyte damage and therefore minor elevations of cTn is broad and includes acute and chronic cardiac disorders. The
differential diagnosis of larger amount of injury and therefore more substantial elevations of cTn is largely restricted to AMI, myocarditis, and
a rare patient with tako-tsubo cardiomyopathy.
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Introduction
Recent advances in assay technology have led to a refinement in
cardiac troponin (cTn) I and T assays and therefore the clinical
ability to detect and quantify cardiomyocyte injury.1–3
Cardiac troponins are structural proteins unique to the heart. De-
tection of cTn in peripheral blood indicates cardiomyocyte damage.
It is an unresolved issuewhether cardiomyocyte damage as indicated
by cTn always reflects myocardial cell death.1,4 –6 In the absence of a
sufficiently sensitive in vivo method to prove the integrity of the
cardiomyocytes despite cTn release, we suggest that any damage
identified by cTn release should be considered irreversible. This
concept is supported by autopsy studies indicating substantial loss
of cardiomyocytes during the course of life.7
As acute myocardial infarction (AMI) is the most important
cause of myocardial cell death, the use of high-sensitive cTns
(hs-cTns) might be expected to lead to important improvements
in the diagnosis AMI.8 This review will highlight the most relevant
aspects of the issues involved from a clinical perspective and
provide suggestions on how to best clinically apply hs-cTns.
Is there an unmet clinical need that high sensitivity cTns could
assist with? We would suggest that there are at least two.
Early and reliable diagnosis of
acute myocardial infarction
Acute myocardial infarction is the major cause of death and disabil-
ity worldwide with an ongoing increase in incidence. The risk of
death is highest within the first hours from AMI onset.9–11 Ap-
proximately 15–20 million patients per year present to the emer-
gency department (ED) with acute chest pain or other symptoms
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suggestive of AMI in Europe and the USA.9–11 Rapid identification
of patients at risk facilitates effective evidence-based medical treat-
ment and management.10–12 In addition, since the majority of
patients presenting with acute chest pain do NOT have acute is-
chaemia, but rather benign disorders, the rapid identification of
these patients would substantially reduce ED overcrowding,
which is a major problem associated with increased morbidity
and even mortality in multiple studies.13
The 12-lead electrocardiogram (ECG) and cTn are the diagnos-
tic cornerstones and complement clinical assessment (Figures 1 and
2).10–12 In most patients with ST-elevation AMI, clinical assessment
and the ECG provide a straightforward diagnosis and allow the ini-
tiation of revascularization within minutes. However, ST-elevation
AMI represents only about 5% of consecutive patients presenting
with acute chest pain.14 Therefore, in many other patients, in
fact the vast majority, the physician is left with considerable uncer-
tainty after the clinical assessment and the initial ECG. The ECG by
itself is often insufficient to diagnose as AMI ST deviation is non-
specific and is observed in other conditions such as early repolar-
ization patterns, acute pericarditis, left ventricular hypertrophy, left
bundle brunch block, hyperkalaemia, and the Brugada syn-
drome.10–12,15,16 Therefore, cTn values have a prominent role in
the diagnosis of AMI and in identifying patients with acute coronary
syndromes at high risk who will benefit from aggressive anticoagu-
lation with antithrombin agents, IIB/IIIA platelet agents,10–12,17–22
early coronary angiography, and whenever possible percutaneous
coronary intervention.14,16 Cardiac troponins which are sensitive
and specific biochemical markers of cardiomyocyte damage are
helpful in clinical practice in identifying patients with acute
coronary syndromes at high risk and in selecting those patients
who will benefit from early non-invasive and invasive treatment
such as coronary angiography and whenever possible percutan-
eous coronary intervention.17–22 In addition, fully automated
standard cTn assays are superior to other biomarkers that have
been clinically available for the diagnosis of AMI and therefore
are considered the preferred marker in the diagnosis of
AMI.18,20,23–25
A major limitation of the earlier generations of cTn assays is that
they have a period during the first hours of AMI where they are
not elevated. With these assays, circulating levels become detect-
able in peripheral blood only after 3–4 h.10–12,26 Thus, the diagno-
sis of AMI can require prolonged monitoring over 6–12 h and
serial blood sampling (Figure 2) because there often is substantial
ambiguity about the time of onset of any given ischaemic event.
Delays in ‘ruling in’ AMI delay therapy and may increase morbidity
and potentially mortality in AMI.10–12 Delays in ‘ruling out’ contrib-
ute to overcrowding in the ED and the associated costs probably
exceeding several billion US dollars each year.27
Figure 3 highlights the main difference between contemporary
and hs-cTns assays. High-sensitive cTn assays have two differentiat-
ing features from contemporary cTn assays: (i) detection of cTn in
a larger number of healthy persons and (ii) a more precise defin-
ition of what is ‘normal’ (¼the 99th percentile).12,14,28 This
feature is of key importance as a cTn value above the 99th percent-
ile of a normal reference population is a ‘condition sine qua non’
for the diagnosis of AMI.
Detection of other disease entities
that damage the heart and
adversely influence prognosis
A variety of processes can lead to increases in cTn and they invari-
ably reflect a significant structural or functional cardiac abnormal-
ity, usually with important prognostic significance. For example,
elevations identify patients with adriamycin cardiotoxicity29,30 and
those with severe carbon monoxide toxicity31 and help to identify
high-risk patients who are acutely ill.32 More sensitive and more
precise diagnosis will likely help to identify more such disease en-
tities and thus provide opportunities to improve patient care and
with it prognosis. The landmark work of Cardinale et al. in diagnos-
ing and development effective treatments for adriamycin cardio-
toxicity serve as a prescient example.29
High-sensitive cardiac troponin
assays
‘Sensitive’ and ‘high-sensitive’ are used by the manufacturer to de-
scribe their assays with increased sensitivity.33–35 Although there is
no consensus when the terms ‘sensitive’ and ‘high or ultra-
sensitive’ should be applied in the description of cTn assays, it is
important to note that there are substantial analytical differences
among the new assays. Some allow the detection of cTn in
50% of a normal reference population and other in up to 90%
of a normal reference population (Figure 3). One reasonable
option is to use ‘sensitive’ for the former and ‘high-sensitive’ for
the later.36,37
Gain: sensitive and high-sensitive
cardiac troponin assays improve
the early diagnosis of acute
myocardial infarction
Two large prospective multicentre studies have demonstrated that
sensitive cTn and hs-cTn assays have a higher diagnostic accuracy at
the time of presentation for the diagnosis of AMI than less sensitive
cTn assays (Figure 4). The benefit observed for sensitive and high-
sensitive assays was most pronounced in patients presenting early
after chest pain onset.37,38 Many of the assays used in these studies
are available for routine use but often have been used with cut-off
values higher than the 99th percentile value. Regardless of the
assay, the use of the 99th percentile value is essential for the
optimal use of any cTn assay. Improvements in the early diagnosis
of AMI in the ‘early presenters’ would offer the opportunity to test
again whether early intervention in non-ST-elevation myocardial
infarction (STEMI) patients might be beneficial as it is in STEMI
patients.10–12 It may be that late presentation combined with the
substantial time it takes to confirm the diagnosis has contributed
substantially to the negative trials in this area. In addition, the sen-
sitive cTn and hs-cTn assays will allow the reliable ‘rule out’ of AMI
within a much shorter period than standard cTn assays. Used in
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conjunction with clinical assessment and the ECG, sensitive cTn
and hs-cTn assays may significantly reduce the percentage of
patients with diagnostic uncertainty who require continuous
ECG monitoring and serial blood sampling. They also have the
potential to obviate the need for subsequent stress testing. The
cost-savings associated with this increase in earlier and more com-
prehensive diagnostic accuracy might be substantial.27 Ongoing
studies by our group and others will define the best algorithms
on how to apply these cTn assays to most rapidly rule-out and
rule-in AMI. It is very likely that the novel high-sensitivity assays
mentioned above will facilitate this process. For now, it appears
that although reduced, there still may be patients with unstable
angina without elevations in cTn that may require urgent care
but this issue will require additional data. One may eventually
(sic) be able to argue that without an increase in cTn, an unstable
syndrome is not present.
The universal definition of AMI in 2007 identified different sub-
types of AMI for the first time.12 The designation of AMI is no
longer restricted to those with acute coronary plaque rupture
resulting in decreased oxygen supply (Type I) but also in conditions
with elevated oxygen demand (Type II, e.g. sepsis, hypertensive
crisis, tachycardic atrial fibrillation) in the absence of a dominant
coronary atherosclerosis, endothelial dysfunction, vasospasm, or
coronary embolism.39,40 It is opined that values of cTn may be
lower in this group. If so, with the clinical launch of hs-cTn
assays, this type of AMI will be diagnosed more often and it still
has to be shown whether these patients profit from acute imple-
mentation of aggressive dual platelet inhibition, aggressive
anti-coagulation, and an early invasive strategy as those with
acute plaque rupture seem to.
Challenge: how to identify the
cause of cardiomyocyte damage?
The hs-cTnT assay is the first hs-cTn assay available for widespread
clinical application. Following the publication of the data showing
superior performance in the early diagnosis of AMI, also various
clinically important subgroups such as the elderly,41 many
Figure 1 Twelve-lead electrocardiogram and measurement of cardiac troponin complement clinical assessment in the diagnosis of acute
myocardial infarction. The unstable angina group is very likely to shrink significantly with the use of sensitive and high sensitivity cardiac troponin
assays.
Figure 2 Rule-in of acute myocardial infarction can be at pres-
entation (0 h) in patients with unequivocal ST-elevations, at 1 h in
patients with elevations in cardiac troponin (cTn) in the measure-
ment performed at presentation (turnaround time is around 1 h
in most hospitals), and at 7 h if the first cardiac troponin is normal
and the elevation in cardiac troponin becomes apparent only at
the second measurement performed after 6 h. Rule-out requires
a normal second cardiac troponin level and therefore 7 h.
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institutions throughout Europe have replaced the contemporary
cTnT assay with the hs-cTnT assay. While this transition is technic-
ally easy as both assays run on the same platform and the hs-cTnT
assay is comparably priced, the challenges faced on the clinical side
have been substantial and largely underestimated. Many institutions
have switched assays with little educational efforts to prepare their
clinicians on how to best apply the hs-cTnT test results.
Also, many institutions in Europe and in the USA are ill-prepared
for the transition to the hs-cTn assays. Although some already
were using a sensitive cTn assay, many institutions did not apply
the cut-off level suggested by the current guidelines (the 99th per-
centile or even, though not recommended, the first higher concen-
tration, fulfilling a coefficient of variation of less than 10%),12,14,28
but rather used a higher cut-off level because it provides higher
specificity for AMI. This approach was recently studied with a con-
temporary assay and the use of a higher cut-off value was asso-
ciated with substantial increases in morbidity and mortality than
the use of a lower cut-off value in this study.42 However, it is im-
portant to note that the lower cut-off value applied was still higher
than the 99th percentile, which would have been the cut-off value
recommended in the universal definition.12,14,28
For years, the clinical application of cTn results was rather
simple. An elevated cTn level was considered equivalent to the
diagnosis of an acute coronary syndrome and justified the immedi-
ate initiation of antiplatelet and anticoagulation therapy, transfer to
the coronary care unit, and cardiology consultation for early cor-
onary angiography and intervention.10–12,17–22
The clinical introduction of sensitive and hs-cTn assays is a
trade-off. They will allow the detection and eventually the exclu-
sion of AMI in the first hours but also the detection of myocardial
Figure 3 Interpretation of cardiac troponin concentrations in clinical practice, and changes offered by the consideration high-sensitive cardiac
troponin. The main difference between contemporary cardiac troponin T (right, fourth-generation Roche cTnT) and high-sensitive cardiac
troponin T (left) is that the latter allows a precise definition of the normal range. For cardiac troponin T, two different cut-off levels have
been used. Levels of ,0.01 mg/L are undetectable and considered ‘normal’. Levels between 0.01 and 0.035 mg/L are ‘likely pathological’ but
associated with high imprecision, and levels above 0.035 mg/L are pathological. The high-sensitive cardiac troponin T assay detects many patients
with previously undetectable cardiac troponin T levels who have high-sensitive cardiac troponin T levels above the 99th percentile explaining
why most of these patients appear to be at risk.
Figure 4 Diagnostic accuracy at presentation as quantified by
the area under the receiver operating characteristic (ROC)
curves for a contemporary cardiac troponin assay (black, fourth-
generation cardiac troponin T) and four sensitive or high-sensitive
cardiac troponin assays (red, Siemens cTnI Ultra; blue, Abbott
cTnI Architect; green, Roche high-sensitivity cTnT; orange,
Roche cTnI) in the diagnosis of acute myocardial infarction
according to chest pain onset.
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cell death associated with multiple other pathophysiological situa-
tions as well and will challenge the clinician to differentiate them.
We are just beginning to understand the potential associated
with the use of hs-cTn assays for these multiple other indications.
These tools allow us to detect cardiomyocyte damage in the stable
phase of established cardiac disease like coronary artery disease
(CAD)43 or heart failure, or even to identify in the general popu-
lation those patients with either silent or clinically underestimated
cardiac disease and therefore high risk of death.1–3,44 They facili-
tate the detection of the toxic effects of drugs and internal and/
or external toxins which will in the long run lead to the avoidance
of toxic treatments and approaches to mitigate the effects of those
that cannot be avoided. Perhaps, had they been used during the de-
velopment of peroxisome proliferator-activated receptor agonists
and coxibs,45 we might have avoided the difficulty associated with
those therapies.
High-sensitive cardiac troponin
improves risk stratification
It is instructive to use stable CAD as an example to discuss the po-
tential clinical use and challenges associated with hs-cTn assays in
risk stratification. In most patients with putatively stable CAD, cTn
levels in peripheral blood are below the limit of detection for con-
ventional assays. However, some of these patients do have eleva-
tions and they are associated with an adverse prognosis over
time.46,47 In addition, detectable levels aremore common in patients
with disease undergoing angiography.48 Recent data with the
hs-cTnT assay frompatientswith stable CADand preserved left ven-
tricular ejection fraction function suggest that with high-sensitivity
assays, more patients at risk can be identified.43 High-sensitive
cTnT levels were detectable in more than 90% of the patients and
above the 99th percentile in 11% of the patients. After adjustment
for several independent prognostic indicators, there was a strong
and graded increase in the cumulative incidence of cardiovascular
death and heart failure. In a large multiethnic population-based
cohort, detectable levels of hs-cTnT were shown to be associated
with higher all-cause mortality.3 Increased risk associated with
higher levels of cTnT was evident well below the limit of detection
of conventional cTn T assays and even below the 99th percentile
of values in a healthy population. These data correlate nicely with
the graded relationship between the extent of CAD and hs-cTnT
shown by Laufer et al.49 Of interest, men had higher values than
women for any given anatomic subset. In a first attempt at defining
subgroups in this area, Schulz et al.,50 using a novel hs-cTnI assay,
could not find a relationship to the extent of CAD or prognosis
and high-sensitivity values in a cohort of putatively stable patients
undergoing elective coronary angiography.
Given these data and the reference range data which suggest
lower values in women,51 it may be that different values will be ne-
cessary based on gender. This could also be the case with race
given the recent data of de Lemos et al.3 The next step now is
to prove that we have treatment modifications to offer to patients
identified to be at increased risk that ultimately improve patient
outcome. Using a pre-commercial hs-cTnI assay in a heteroge-
neous group of patients with diverse aetiologies for cardiac
disease, values were not helpful in distinguishing the aetiology of
the elevations or in predicting prognosis.50
Clinical application of
high-sensitive cardiac troponin
assays: absolute level and change
Since AMI is not the only cause of cardiomyocyte damage, it is key
to consider the absolute level as well as the change in cTn early
after presentation as important criteria in the differential diagnosis
of the cause of cardiomyocyte damage (Figure 5). Higher values are
more often due to AMI and/or myocarditis. Thus, the higher the
value of cTn at ED presentation, the higher the probability of
AMI.1–3 The differential diagnosis of mild elevation of cTn and
therefore mild cardiomyocyte damage is broad and includes both
acute and chronic disorders. Thus, the terms troponin ‘positive’
and ‘negative’ should be avoided.
Secondly, the larger the rise in the hs-cTn within the first hours
in the ED is, the higher is the probability that it is caused by AMI.
When AMI is overt, marked changes are present with changes well
over 100%.52 Chronic cardiac disease including stable angina exhi-
bits more constant cTn levels. How to define a changing pattern of
cTn is unsettled. Unresolved questions include whether to use ab-
solute or relative changes to best separate acute from chronic cTn
elevations, as well as the specific values for use in the diagnosis of
AMI (what changes in what time interval). Several groups have
advocated the use of a criterion of 50% based on the biological
variation of another hs-cTn assay.53 However, in a recent study,
the area under the receiver operating characteristic (ROC) curve
for diagnosing AMI was significantly higher for 2 h absolute vs.
2 h relative cTn changes. The ROC curve-derived cut-off value
for 2 h absolute change was 0.007 mg/L for hs-cTnT and
0.020 mg/L for cTnI ultra (both cut-off levels are half of the 99th
percentile of the respective cTn assay). Absolute changes were su-
perior to relative changes in patients with both low and elevated
baseline cTn levels.54 Data from other groups will soon become
available and help to provide more definite recommendations.
Figure 5 The differential diagnosis of high-sensitive cardiac
troponin T (hs-cTnT) levels is highly dependent on the absolute
level.
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However, an ROC determined value is a balance between sensitiv-
ity and specificity and one might want, in this situation, to use the
minimum delta associated with an acute event rather than the
ROC value in the interest of not missing patients potentially at risk.
However, it is important to highlight that detailed clinical assess-
ment remains mandatory to differentiate AMI from the other po-
tential causes of myocardial injury. Some have advocated the use of
biological variation to inform this measurement.55,56 At present,
however, it is unclear what the proper metric is. Indeed, it is not
the optimal delta that is of importance but the minimum delta
that should inform this decision. It should also be appreciated
that these highly sensitive assays and change criteria will be badly
confounded by analytic problems such as haemolysis57 and/or
other analytic problems because such small changes are of import-
ance.58 Once we understand how to use these metrics, we will be
able to address whether AMI and unstable angina are different or
similar diseases on the myocardial level.59
As indicated above, an elevated value of cTn is associated with
drug toxicities, patients with acute heart failure, and critically ill
patients as well. These elevations are highly prognostic.29,30,32
With hs-cTn assays, more such elevations will be detected.60
The most appropriate management of these groups is still
unknown but they are at greater short- and long-term risk and
we have an obligation as clinicians to make sure that at least indi-
cated prevented care of risk factors is undertaken.
Ongoing studies will define the best algorithms on how to apply
the data from hs-cTn assays in clinical practice. Rule-out and rule-in
algorithms as well as the timing of the second measurement will
have to be fine-tuned for each specific cTn assay. Preliminary
data suggest that the hs-cTn assays will allow the reliable
rule-out of AMI in many patients within 1–3 h from presentation
to the ED.11,12,61 It is important to note that the diagnostic per-
formance of sensitive cTn assays in the diagnosis of AMI outside
the setting of chest pain patients presenting to the ED is unknown.
The more widespread application of sensitive and hs-cTn tests
and the application of the 99th percentile as the decision limit
for AMI will lead to a substantial increase in the detection of
patients with slightly elevated levels of cTn. In some of them,
AMI will be the diagnosis, and in many others, the mechanisms
of myocardial injury will not be AMI. Future studies need to
define the most appropriate therapeutic measures in response to
the detection of myocardial injury in many of these settings.
Sensitive and hs-cTn assays provide a new non-invasive window
to the heart. We should not be afraid of having a closer look.
Accepting that we do not fully understand all what we see
through this novel window is a crucial step to direct future re-
search in the right direction in order to improve the management
of patients with cardiovascular disorders.
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Early calcific degeneration of a CoreValve transcatheter aortic bioprosthesis
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A 74-year-old man, one of the first few patients
in the world to undergo transcatheter aortic
valve implantation (TAVI) with the porcine
CoreValve bioprosthesis presented with dyspnoea
after 5 years. Echocardiogram and cardiac cath-
eterization, respectively, revealed and confirmed
bioprosthetic degenerative restenosis. The mean
gradient across the CoreValve on transthoracic
Doppler was 53 mmHg and pull-back gradient
at catheterization was 79 mmHg. Aortic insuffi-
ciency was only mild. Of note, echocardiography
1 year earlier was unremarkable. In the absence
of very high surgical risk, he underwent surgical
bioprosthetic replacement. Extensive calcifica-
tion of the explanted CoreValve’s leaflets was
noted both on the outflow and inflow surfaces.
Although a rare event so early after CoreValve
implantation, he was among the earliest patients.
Appropriate patient selection and vigilance to
determine long-term CoreValve durability is paramount, particularly with the interest in extending TAVI to lower-risk patients.
Figure: Degenerated CoreValve. Panel (A) shows the continuous wave Doppler tracing across the aortic bioprosthesis on transthor-
acic echocardiography with a mean gradient of 53 mmHg. Panel (B) demonstrates the aortic pull-back gradient of 79 mmHg during
cardiac catheterization. Surgical extraction of the degenerated CoreValve prosthesis was performed (C ). Panels (D) and (E) demon-
strate the extensive calcification on the outflow and inflow aspects of the porcine leaflets, respectively.
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